NOD1 and cancer: NOD1 also increased hepatocellular carcinoma HCC chemosensitivity to sorafenib or 5-FU therapy by decreasing the SRC-MAPK signaling pathway and inhibited HCC cancer cell growth in vitro and in vivo [28].